Güler YAVAŞ, Esra KORKMAZ KIRAKLI, Meltem DAĞDELEN, Erkan TOPKAN, Mert SAYNAK, Fazilet ÖNER DİNÇBAŞ, Yurday ÖZDEMİR, Çağdaş YAVAŞ, Sümerya Duru BİRGİ, Serap AKYÜREK

Role of Consolidative Thoracic Radiotherapy for Extensive-stage Small Cell Lung Cancer: Trod Thoracic Oncology Study Group 08-006 Multi-institutional Study

OBJECTIVE We aimed to evaluate the role of consolidative thoracic radiotherapy (TRT) in patients with extensive stage small cell lung cancer (ES-SCLC). METHODS The clinical data for 151 patients with the diagnosis of ES-SCLC treated with consolidative TRT from six different hospitals from Turkey analyzed. RESULTS The median age of the patients was 61 years (range 36-83 years). The median dose of radiotherapy (RT) was 45 Gy (range: 30-66 Gy) applied in median 25 fractions (range 10-34 fractions). For 151 assessable patients, the median survival time (MST) was 14 months (range: 12.6-15.3). The patients who has com plete response and partial response had 16 months, and 14 months of MST. In multivariate analyses pro phylactic cranial irradiation (PCI) (p=0.011), female gender (p=0.017), and comorbidity (p=0.006) were found as significant parameters associated with survival. The MSTs were 12 months in patients without comorbidity, and 16 months for the patients with at least one comorbid disease. The patients who received PCI had improved MSTs when compared the ones without PCI (16 months vs. 12 months). There was a trend towards improved overall survival times in patients who received EQD2 ≥47 Gy RT doses (p=0.08). CONCLUSION Female gender, use of PCI, and unavailability of comorbid disease were associated with improved sur vival in ES-SLCL patients. There was a trend towards overall survival times in patients who received ≥47 Gy EQD2 doses; however, we believe that this statistical insignificance was related to our limited patient numbers.

PDF

___

1. van Meerbeeck JP, Fennell DA, de Ruysscher DK. Smallcell lung cancer. Lancet 2011;378(9804):1741– 55.
2. Houston KA, Henly SJ, Li J, White MC, Richards TB. Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. Lung Cancer 2014;86(1):22–8.
3. Früh M, de Ruysscher D, Popat S, Crinò L, Peters S, Felip E, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi99–105.
4. Byers LA, Rudin CM. Small cell lung cancer: Where do we go from here? Cancer 2015;121(5):664–72.
5. Slotman BJ, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357(7):664–72.
6. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavl jevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with ex tensive disease small-cell lung cancer: A randomized study. J Clin Oncol 1999;17(7):2092–9.
7. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic ra diotherapy for extensive stage small-cell lung can cer: A phase 3 randomised controlled trial. Lancet 2015;385(9962):36–42.
8. Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized Phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative ex tra-cranial irradiation for extensive disease small cell lung cancer (ED-SCLC): NRG oncology RTOG 0937. J Thorac Oncol 2017;12(10):1561–70.
9. Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic radiotherapy for extensive stage small-cell lung cancer: A meta-analysis. Clin Lung Cancer 2016;17(4):239–44.
10.Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Eur J Cancer 2019;110:110–9.
11.Li-Ming X, Zhao LJ, Simone CB 2nd, Cheng C, Kang M, Wang X, et al. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol 2017;125(2):331–7.
12.Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Weg ner RE. Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A na tional cancer database (NCDB) propensity-matched analysis. Lung Cancer 2018;124:283–90.
13.Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, et al. Which patients with ES SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer 2017;108:150–3.
14.Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Casas F, Filipovic N. Radiation therapy in extensive stage small cell lung cancer. Front Oncol 2017;7:169.
15.Xu LM, Cheng C, Kang M, Luo J, Gong LL, Pang QS, et al. Thoracic radiotherapy (TRT) improved survival in both oligo-and polymetastatic extensive stage small cell lung cancer. Sci Rep 2017;7(1):9255.
16.Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small cell lung cancer: A multicentre, randomised, open-la bel, phase 3 trial. Lancet Oncol 2017;18(5):663–7.